Clinical Trial

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Investigators target recurrent nasopharyngeal carcinoma that can be resected surgically: rT1, rT2 (tumor confined to the surface of the parapharyngeal space, greater than 0.5cm from the internal carotid artery), rT3 (confined to the floor of the sphenoid sinus, greater than 0.5cm from the internal carotid artery/cavernous sinus) (AJCC 8th stage), A single-arm, phase II clinical trial was designed to investigate the efficacy and safety of triplizumab combined with nituzumab in induction and adjuvant treatment of operable local recurrent nasopharyngeal carcinoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-03; most recent amendment 2025-05-15.
Status change: Not Yet Recruiting → Recruiting 2025-05-15
Trial Details
NCT Number NCT06912711
Lead Sponsor Sun Yat-sen University
Conditions Nasopharyngeal Carcinoma
Enrollment 70 participants
Start Date 2025-05-16
Primary Completion 2029-04-20 (estimated)
Study Completion 2029-04-20 (estimated)
Updated on ClinicalTrials.gov 2025-05-21